WHI
ESPR

William Harris Investors’s Esperion Therapeutics ESPR Stock Holding History

William Harris Investors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-65,000
Closed -$916K – 93
2013
Q2 		$916K Buy
+65,000
New +$923K 0.28% 48

Other funds holding ESPR

PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return

William Harris Investors's ESPR Position: Q3 2013 in Review

William Harris Investors sold out of Esperion Therapeutics (ESPR) in Q3 2013, closing a stake of 65,000 shares — an estimated $916K sold.

William Harris Investors first reported a position in ESPR in Q2 2013 and held it in 1 quarter. The position peaked at $916K in Q2 2013. 44 funds tracked by Wall St. Rank hold ESPR as of Q3 2013.

  • William Harris Investors reported no remaining Esperion Therapeutics position as of Q3 2013 after selling out during the quarter.
  • William Harris Investors sold 65,000 Esperion Therapeutics shares in Q3 2013, an estimated $916K.
  • William Harris Investors first reported a position in Esperion Therapeutics in Q2 2013 and held it in 1 quarter.
  • William Harris Investors's Esperion Therapeutics position peaked at $916K in Q2 2013.
  • 44 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2013.

Based on William Harris Investors's 13F filing for Q3 2013, filed 13 Nov 2013.